Palisade Bio, Inc. Common Stock
PALIPalisade Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for gastrointestinal and other chronic conditions. Its pipeline emphasizes targeted treatments designed to improve patient outcomes by addressing underlying disease mechanisms.
Company News
Palisade Bio has canceled its previously adjourned special stockholders meeting due to lack of quorum and will withdraw proposals previously submitted for consideration.
Palisade Bio, a clinical-stage biopharmaceutical company, announced an equity grant of 2,600 stock options to a new employee as an inducement to employment.
Live video webcast on Wednesday, June 26th at 4:00 PM ET
– Collaboration advancing Palisade Bio’s precision medicine approach through access to cutting-edge expertise and tools in bioinformatics
Palisade Bio (PALI) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
